12 Month Price Forecast For VIGL
Distance to VIGL Price Forecasts
VIGL Price Momentum
๐ค Considering Vigil (VIGL)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 6, 2025 9:08 AM UTC
VIGL Analyst Ratings & Price Targets
Based on our analysis of 9 Wall Street analysts, VIGL has a consensus that is bullish. The median price target is $17.00, with forecasts ranging from $4.00 to $24.00. Currently, there are 8 Buy ratings, 0 Hold ratings, and 1 Sell ratings.
With VIGL currently trading at $2.73, the median price forecast suggests a 522.7% upside. The most optimistic forecast comes from Laura Chico at Wedbush, projecting a 779.1% upside, while Jeffrey Hung at Morgan Stanley provides the most conservative target, suggesting a 46.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
VIGL Analyst Consensus
VIGL Price Target Range
Latest VIGL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for VIGL.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Jan 24, 2025 | Guggenheim | Yatin Suneja | Buy | Reiterates | $0.00 |
Jan 23, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $17.00 |
Dec 4, 2024 | William Blair | Sarah Schram | Outperform | Initiates | $0.00 |
Nov 26, 2024 | JMP Securities | Jason Butler | Market Outperform | Reiterates | $22.00 |
Nov 8, 2024 | Wedbush | Laura Chico | Outperform | Maintains | $24.00 |
Nov 8, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $17.00 |
Aug 14, 2024 | Guggenheim | Yatin Suneja | Buy | Maintains | $16.00 |
Aug 14, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $17.00 |
Jul 25, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $17.00 |
Jul 19, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $17.00 |
Jul 11, 2024 | Wedbush | Laura Chico | Outperform | Reiterates | $23.00 |
Jun 28, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $24.00 |
Jun 28, 2024 | Wedbush | Laura Chico | Outperform | Maintains | $23.00 |
May 8, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $24.00 |
May 8, 2024 | Wedbush | Laura Chico | Outperform | Reiterates | $22.00 |
Apr 19, 2024 | JMP Securities | Jason Butler | Market Outperform | Reiterates | $23.00 |
Apr 18, 2024 | JMP Securities | Jason Butler | Market Outperform | Reiterates | $23.00 |
Mar 27, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $24.00 |
Dec 19, 2023 | Morgan Stanley | Jeffrey Hung | Underweight | Downgrade | $4.00 |
Nov 17, 2023 | Wedbush | Laura Chico | Outperform | Reiterates | $23.00 |
Stocks Similar to Vigil Neuroscience, Inc.
The following stocks are similar to Vigil based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Vigil Neuroscience, Inc. (VIGL) Financial Data
Vigil Neuroscience, Inc. has a market capitalization of $103.02M with a P/E ratio of -1.3x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -70.1%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Vigil Neuroscience, Inc. (VIGL) Company Overview
About Vigil Neuroscience, Inc.
Develops treatments for neurodegenerative diseases.
Vigil Neuroscience operates as a clinical-stage biotechnology company, focusing on developing innovative treatments for neurodegenerative diseases by targeting the immune response in the brain. The company generates revenue through licensing agreements, such as its partnership with Amgen Inc., which allows for the commercial development and sale of TREM2-targeting therapeutic products.
With its lead candidate VGL101 in Phase 2 trials for a rare disease and VG-3927 in Phase 1 trials for Alzheimer's, Vigil Neuroscience is positioned to address significant unmet medical needs in neurodegenerative disorders. Founded in 2020 and based in Watertown, Massachusetts, the company is tapping into a critical area of healthcare with potential for substantial market impact.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
64
CEO
Dr. Ivana Magovcevic-Liebisch J.D., Ph.D.
Country
United States
IPO Year
2022
Website
www.vigilneuro.comVigil Neuroscience, Inc. (VIGL) Latest News & Analysis
Vigil Neuroscience, Inc. (Nasdaq: VIGL) will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on February 6, 2025, at 10:30 a.m. ET.
Vigil Neuroscience's participation in a prominent biotech conference highlights its visibility and credibility, potentially influencing investor sentiment and stock performance.
Vigil Neuroscience Inc. (VIGL) announced results from its completed Phase 1 trial for VG-3927, a potential Alzheimer's disease treatment, on Thursday.
Vigil Neuroscience's Phase 1 trial results for VG-3927 could indicate the drug's viability, impacting stock performance and investor sentiment in the biotech sector focused on Alzheimer's treatments.
VG-3927 shows promising safety and efficacy for treating Alzheimer's disease, supporting its further development as a potential once-daily oral therapy.
VG-3927โs promising profile for Alzheimer's treatment may attract investment in biotech, signaling potential market growth and increased competition in the Alzheimer's drug sector.
VG-3927 is set to report Phase 1 clinical trial data for Alzheimer's disease in Q1 2025.
Progress in VG-3927's Phase 1 trial could signal potential breakthroughs in Alzheimer's treatment, impacting stock valuations and investor sentiment in biotech sectors.
Purcell & Lefkowitz LLP is investigating Vigil Neuroscience, Inc. (NASDAQ: VIGL) for potential breaches of fiduciary duties by its directors regarding recent corporate actions.
The investigation into Vigil Neuroscience's directors may signal potential governance issues, impacting shareholder trust and the company's stock performance.
Vigil Neuroscience (Nasdaq: VIGL) announced the FDA lifted the partial clinical hold on its Phase 1 trial for VG-3927, following a complete response from the company.
The FDA's removal of the clinical hold allows Vigil Neuroscience to advance its Phase 1 trial, potentially accelerating drug development and increasing investor confidence in its future.
Frequently Asked Questions About VIGL Stock
What is Vigil Neuroscience, Inc.'s (VIGL) stock forecast for 2025?
Based on our analysis of 9 Wall Street analysts, Vigil Neuroscience, Inc. (VIGL) has a median price target of $17.00. The highest price target is $24.00 and the lowest is $4.00.
Is VIGL stock a good investment in 2025?
According to current analyst ratings, VIGL has 8 Buy ratings, 0 Hold ratings, and 1 Sell ratings. The stock is currently trading at $2.73. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for VIGL stock?
Wall Street analysts predict VIGL stock could reach $17.00 in the next 12 months. This represents a 522.7% increase from the current price of $2.73. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Vigil Neuroscience, Inc.'s business model?
Vigil Neuroscience operates as a clinical-stage biotechnology company, focusing on developing innovative treatments for neurodegenerative diseases by targeting the immune response in the brain. The company generates revenue through licensing agreements, such as its partnership with Amgen Inc., which allows for the commercial development and sale of TREM2-targeting therapeutic products.
What is the highest forecasted price for VIGL Vigil Neuroscience, Inc.?
The highest price target for VIGL is $24.00 from Laura Chico at Wedbush, which represents a 779.1% increase from the current price of $2.73.
What is the lowest forecasted price for VIGL Vigil Neuroscience, Inc.?
The lowest price target for VIGL is $4.00 from Jeffrey Hung at Morgan Stanley, which represents a 46.5% increase from the current price of $2.73.
What is the overall VIGL consensus from analysts for Vigil Neuroscience, Inc.?
The overall analyst consensus for VIGL is bullish. Out of 9 Wall Street analysts, 8 rate it as Buy, 0 as Hold, and 1 as Sell, with a median price target of $17.00.
How accurate are VIGL stock price projections?
Stock price projections, including those for Vigil Neuroscience, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.